Oric Pharmaceuticals (ORIC) Competitors $10.77 +0.12 (+1.13%) Closing price 07/3/2025 02:18 PM EasternExtended Trading$10.78 +0.02 (+0.14%) As of 07/3/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. MTSR, KYMR, VKTX, MOR, CRNX, ALVO, MLTX, CPRX, IMVT, and HCMShould you be buying Oric Pharmaceuticals stock or one of its competitors? The main competitors of Oric Pharmaceuticals include Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), MoonLake Immunotherapeutics (MLTX), Catalyst Pharmaceuticals (CPRX), Immunovant (IMVT), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oric Pharmaceuticals vs. Its Competitors Metsera Kymera Therapeutics Viking Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech MoonLake Immunotherapeutics Catalyst Pharmaceuticals Immunovant HUTCHMED Oric Pharmaceuticals (NASDAQ:ORIC) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Is ORIC or MTSR more profitable? Metsera's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.14% -46.29% Metsera N/A N/A N/A Does the media prefer ORIC or MTSR? In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Metsera. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 1 mentions for Metsera. Metsera's average media sentiment score of 0.59 beat Oric Pharmaceuticals' score of 0.12 indicating that Metsera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Metsera 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ORIC or MTSR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.87-5.76MetseraN/AN/A-$209.13MN/AN/A Do institutionals & insiders hold more shares of ORIC or MTSR? 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 6.8% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate ORIC or MTSR? Oric Pharmaceuticals presently has a consensus target price of $19.17, indicating a potential upside of 77.96%. Metsera has a consensus target price of $55.00, indicating a potential upside of 86.76%. Given Metsera's higher probable upside, analysts clearly believe Metsera is more favorable than Oric Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOric Pharmaceuticals beats Metsera on 5 of the 9 factors compared between the two stocks. Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricOric PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$920.42M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-5.7621.5627.6120.24Price / SalesN/A278.93417.30118.22Price / CashN/A42.7336.8958.10Price / Book3.127.518.035.67Net Income-$127.85M-$55.14M$3.18B$249.21M7 Day Performance4.46%4.61%2.93%3.28%1 Month Performance17.58%4.72%3.75%5.55%1 Year Performance40.05%5.92%35.20%21.09% Oric Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICOric Pharmaceuticals4.1562 of 5 stars$10.77+1.1%$19.17+78.0%+43.2%$920.42MN/A-5.7680MTSRMetseraN/A$29.00-2.0%$55.00+89.7%N/A$3.11BN/A0.0081Gap DownKYMRKymera Therapeutics3.1711 of 5 stars$46.29+0.9%$59.82+29.2%+48.6%$2.99B$47.07M-14.93170Positive NewsAnalyst ForecastInsider TradeVKTXViking Therapeutics4.3603 of 5 stars$24.86-4.4%$87.15+250.6%-44.2%$2.92BN/A-21.6220Trending NewsInsider TradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730News CoverageCRNXCrinetics Pharmaceuticals3.3052 of 5 stars$29.91-0.8%$74.56+149.3%-32.4%$2.82B$1.04M-7.83210ALVOAlvotech3.5282 of 5 stars$9.13-2.4%$18.00+97.2%-24.4%$2.82B$491.98M24.681,032MLTXMoonLake Immunotherapeutics2.1639 of 5 stars$44.87+3.1%$78.71+75.4%+9.9%$2.78BN/A-19.512News CoverageCPRXCatalyst Pharmaceuticals4.9181 of 5 stars$22.12-1.6%$32.83+48.4%+41.3%$2.74B$491.73M14.0980IMVTImmunovant1.4086 of 5 stars$15.47-2.1%$38.33+147.8%-35.9%$2.70BN/A-5.65120HCMHUTCHMED1.3545 of 5 stars$15.21+2.5%$19.00+24.9%-9.3%$2.59B$630.20M0.001,811Positive News Related Companies and Tools Related Companies Metsera Competitors Kymera Therapeutics Competitors Viking Therapeutics Competitors MorphoSys Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors MoonLake Immunotherapeutics Competitors Catalyst Pharmaceuticals Competitors Immunovant Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORIC Stock Alerts